National Center for Advancing Translational Sciences; Notice of Meetings, 56624-56625 [2017-25731]
Download as PDF
pmangrum on DSK3GDR082PROD with NOTICES1
56624
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
Serial No. 201737032671, filed on 09/
14/2017.
All rights in these inventions have
been assigned to the Government of the
United States of America.
The prospective exclusive patent
commercialization license territory may
be worldwide and the field of use may
be limited to: ‘‘Administration to
humans of a GP120-binding protein or
proteins, containing the 6 CDRs of the
N6 antibody, all as described in the
Licensed Patent Rights. This field of use
does not include bi-specific/multispecific constructs utilizing the
Licensed Patent Rights.’’
The N6 antibody has evolved a
unique mode of binding that depends
less on a variable area of the HIV
envelope known as the V5 region and
focuses more on conserved regions,
which change relatively little among
HIV strains. This allows N6 to tolerate
changes in the HIV envelope, including
the attachment of sugars in the V5
region, a major mechanism by which
HIV develops resistance to other VRC01class antibodies. N6 was shown in preclinical studies to neutralize
approximately 98 percent of HIV
isolates tested. The studies also
demonstrate that N6 neutralizes
approximately 80 percent of HIV
isolates which were resistant to other
antibodies of the same class, and does
so very potently. Its breadth and
potency makes N6 a highly desirable
candidate for development in
therapeutic or prophylactic strategies.
An abstract of the subject invention was
published in the Federal Register on
March 13, 2017.
This notice is made in accordance
with 35 U.S.C. 209 and 37 CFR part 404.
The prospective exclusive patent
commercialization license will be
royalty bearing and may be granted
unless within fifteen (15) days from the
date of this published notice, the
National Institute of Allergy and
Infectious Diseases receives written
evidence and argument that establishes
that the grant of the license would not
be consistent with the requirements of
35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in
the prospective field of use that are
timely filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive patent
commercialization license. Comments
and objections submitted in response to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
under the Freedom of Information Act,
5 U.S.C. 552.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
National Institutes of Health
[FR Doc. 2017–25745 Filed 11–28–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Notice of
Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Special Emphasis Panel; AD
Sequencing II.
Date: December 1, 2017.
Time: 1:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institute on Aging,
Gateway Building, Suite 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20814
(Telephone Conference Call).
Contact Person: Bita Nakhai, Ph.D.,
Scientific Review Branch, National Institute
on Aging, Gateway Bldg., 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20814,
301–402–7701, nakhaib@nia.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: November 22, 2017.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25734 Filed 11–28–17; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00045
Fmt 4703
Sfmt 4703
National Center for Advancing
Translational Sciences; Notice of
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of
meetings of the National Center for
Advancing Translational Sciences.
The meetings will be open to the
public as indicated below, with
attendance limited to space available.
Individuals who plan to attend and
need special assistance, such as sign
language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Cures Acceleration
Network Review Board.
Date: January 11, 2018.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Anna L. Ramsey-Ewing,
Ph.D., Executive Secretary, National Center
for Advancing Translational Sciences, 1
Democracy Plaza, Room 1072, Bethesda, MD
20892, 301–435–0809, anna.ramseyewing@
nih.gov.
Name of Committee: National Center for
Advancing Translational Sciences Advisory
Council.
Date: January 11, 2018.
Open: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director
and other staff.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Closed: 3:15 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Building 31, Conference Room 10, 31 Center
Drive, Bethesda, MD 20892.
Contact Person: Anna L. Ramsey-Ewing,
Ph.D., Executive Secretary, National Center
for Advancing Translational Sciences, 1
Democracy Plaza, Room 1072, Bethesda, MD
20892, 301–435–0809, anna.ramseyewing@
nih.gov.
E:\FR\FM\29NON1.SGM
29NON1
Federal Register / Vol. 82, No. 228 / Wednesday, November 29, 2017 / Notices
(Catalogue of Federal Domestic Assistance
Program Nos. 93.859, Pharmacology,
Physiology, and Biological Chemistry
Research; 93.350, B—Cooperative
Agreements; 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Dated: November 22, 2017.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25731 Filed 11–28–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Closed Meeting
pmangrum on DSK3GDR082PROD with NOTICES1
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the NHLBI Special Emphasis
Panel.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Heart, Lung,
and Blood Institute Special Emphasis Panel;
Support for Conference Grants.
Date: December 15, 2017.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Room 7200, Bethesda, MD
20892 (Virtual Meeting).
Contact Person: Michael P. Reilly, Ph.D.,
Scientific Review Officer Office of Scientific
Review, National Heart, Lung, and Blood
Institute, National Institutes of Health, 6701
Rockledge Drive, Room 7200, Bethesda, MD
20892, 301–827–7975, reillymp@
nhlbi.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
Dated: November 22, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2017–25733 Filed 11–28–17; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
15:19 Nov 28, 2017
Jkt 241001
INTERNATIONAL TRADE
COMMISSION
[USITC SE–17–057]
Government in the Sunshine Act
Meeting Notice
United
States International Trade Commission.
TIME AND DATE: December 7, 2017 at
11:00 a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. Nos. 701–TA–566 and
731–TA–1342 (Final) (Softwood Lumber
from Canada). The Commission is
currently scheduled to complete and file
its determinations and views of the
Commission on December 22, 2017.
5. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
AGENCY HOLDING THE MEETING:
By order of the Commission.
Issued: November 27, 2017.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2017–25825 Filed 11–27–17; 4:15 pm]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[USITC SE–17–056]
Government in the Sunshine Act
Meeting Notice
United
States International Trade Commission.
TIME AND DATE: December 5, 2017 at 9:30
a.m.
PLACE: Room 101, 500 E Street SW.,
Washington, DC 20436, Telephone:
(202) 205–2000.
STATUS: Open to the public.
MATTERS TO BE CONSIDERED:
1. Agendas for future meetings: None.
2. Minutes.
3. Ratification List.
4. Vote in Inv. Nos. 701–TA–571–572
and 731–TA–1347–1348 (Final)
(Biodiesel from Argentina and
Indonesia). The Commission is
currently scheduled to complete and file
its determinations and views of the
Commission on December 21, 2017.
AGENCY HOLDING THE MEETING:
PO 00000
Frm 00046
Fmt 4703
Sfmt 4703
56625
5. Outstanding action jackets: None.
In accordance with Commission
policy, subject matter listed above, not
disposed of at the scheduled meeting,
may be carried over to the agenda of the
following meeting.
By order of the Commission.
Issued: November 27, 2017.
William R. Bishop,
Supervisory Hearings and Information
Officer.
[FR Doc. 2017–25824 Filed 11–27–17; 4:15 pm]
BILLING CODE 7020–02–P
INTERNATIONAL TRADE
COMMISSION
[Investigation No. 337–TA–1088]
Certain Road Construction Machines
and Components Thereof; Institution
of Investigation
U.S. International Trade
Commission.
ACTION: Notice.
AGENCY:
Notice is hereby given that a
complaint was filed with the U.S.
International Trade Commission on
October 26, 2017, under section 337 of
the Tariff Act of 1930, as amended, on
behalf of Caterpillar Inc. of Peoria,
Illinois and Caterpillar Paving Products,
Inc. of Minneapolis, Minnesota. A
supplement was filed on November 9,
2017. The complaint, as supplemented,
alleges violations of section 337 based
upon the importation into the United
States, the sale for importation, and the
sale within the United States after
importation of certain road construction
machines and components thereof by
reason of infringement of one or more of
U.S. Patent No. 7,140,693 (‘‘the ’693
patent’’); U.S. Patent No. 9,045,871 (‘‘the
’871 patent’’); and U.S. Patent No.
7,641,419 (‘‘the ’419 patent’’). The
complaint further alleges that an
industry in the United States exists, or
is in the process of being established, as
required by the applicable Federal
Statute.
The complainants request that the
Commission institute an investigation
and, after the investigation, issue a
limited exclusion order and a cease and
desist order.
ADDRESSES: The complaint, except for
any confidential information contained
therein, is available for inspection
during official business hours (8:45 a.m.
to 5:15 p.m.) in the Office of the
Secretary, U.S. International Trade
Commission, 500 E Street, SW., Room
112, Washington, DC 20436, telephone
(202) 205–2000. Hearing impaired
individuals are advised that information
SUMMARY:
E:\FR\FM\29NON1.SGM
29NON1
Agencies
[Federal Register Volume 82, Number 228 (Wednesday, November 29, 2017)]
[Notices]
[Pages 56624-56625]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25731]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Center for Advancing Translational Sciences; Notice of
Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of meetings of the National Center for
Advancing Translational Sciences.
The meetings will be open to the public as indicated below, with
attendance limited to space available. Individuals who plan to attend
and need special assistance, such as sign language interpretation or
other reasonable accommodations, should notify the Contact Person
listed below in advance of the meeting.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Cures Acceleration Network Review Board.
Date: January 11, 2018.
Time: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director.
Place: National Institutes of Health, Building 31, Conference
Room 10, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Anna L. Ramsey-Ewing, Ph.D., Executive
Secretary, National Center for Advancing Translational Sciences, 1
Democracy Plaza, Room 1072, Bethesda, MD 20892, 301-435-0809,
anna.ramseyewing@nih.gov.
Name of Committee: National Center for Advancing Translational
Sciences Advisory Council.
Date: January 11, 2018.
Open: 8:30 a.m. to 3:00 p.m.
Agenda: Report from the Institute Director and other staff.
Place: National Institutes of Health, Building 31, Conference
Room 10, 31 Center Drive, Bethesda, MD 20892.
Closed: 3:15 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Building 31, Conference
Room 10, 31 Center Drive, Bethesda, MD 20892.
Contact Person: Anna L. Ramsey-Ewing, Ph.D., Executive
Secretary, National Center for Advancing Translational Sciences, 1
Democracy Plaza, Room 1072, Bethesda, MD 20892, 301-435-0809,
anna.ramseyewing@nih.gov.
[[Page 56625]]
(Catalogue of Federal Domestic Assistance Program Nos. 93.859,
Pharmacology, Physiology, and Biological Chemistry Research; 93.350,
B--Cooperative Agreements; 93.859, Biomedical Research and Research
Training, National Institutes of Health, HHS)
Dated: November 22, 2017.
David Clary,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-25731 Filed 11-28-17; 8:45 am]
BILLING CODE 4140-01-P